June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
The impact of 1st wave COVID-19 on macular diseases' management in a referral hospital in FRANCE
Author Affiliations & Notes
  • Nabil HERDA
    OPHTHALMOLOGY, Universite Paris-Est Creteil Val de Marne, Creteil, Île-de-France, France
  • Oudy Semoun
    OPHTHALMOLOGY, Universite Paris-Est Creteil Val de Marne, Creteil, Île-de-France, France
  • Juliana ESTRADA WALKER
    OPHTHALMOLOGY, Universite Paris-Est Creteil Val de Marne, Creteil, Île-de-France, France
  • omar moukadem
    OPHTHALMOLOGY, Universite Paris-Est Creteil Val de Marne, Creteil, Île-de-France, France
  • May BAKER
    OPHTHALMOLOGY, Universite Paris-Est Creteil Val de Marne, Creteil, Île-de-France, France
  • Eric H Souied
    OPHTHALMOLOGY, Universite Paris-Est Creteil Val de Marne, Creteil, Île-de-France, France
  • Footnotes
    Commercial Relationships   Nabil HERDA, None; Oudy Semoun, None; Juliana ESTRADA WALKER, None; omar moukadem, None; May BAKER, None; Eric Souied, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 2199. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nabil HERDA, Oudy Semoun, Juliana ESTRADA WALKER, omar moukadem, May BAKER, Eric H Souied; The impact of 1st wave COVID-19 on macular diseases' management in a referral hospital in FRANCE. Invest. Ophthalmol. Vis. Sci. 2021;62(8):2199.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To analyze the impact of the 1st wave COVID-19 on macular diseases' management in ophthalmology department of "Centre hospitalier intercommunal de Créteil (CHIC)" and correlate it with patients’ demographic and clinical features

Methods : Retrospective cross-sectional study. During the lockdown period from March 17th to May 11th, 2020, we analyzed the activity in the medical retina and more specifically intra-vitreal injections (IVIs) and compared it to that of the same period in 2019. The impact of patients’ demographic and clinical features (age, sex, visual acuity (VA), retinal disease, therapeutic strategy) on this activity was evaluated

Results : In 2019, the number of IVIs carried out between March 17th and May 11th, combining all indications was 2189. In 2020, this number was 953 corresponding to a decrease of 56.46 %, statistically significant (p <0.05). During the 1st wave, 767 patients (1020 eyes) were scheduled for at least one IVI. 833 eyes of 615 patients received 1 or 2 scheduled IVIs (Group 1). 187 eyes of 152 patients did not receive any IVIs (Group 2). 83.06% out of the patients in group 1 received all the scheduled IVIs (1 or 2). 16.94% received only a single IVI when they were scheduled to receive a 2nd injection. In group 1, the average age is 76 y. Female patients represent 59.67%. Average VA before lockdown was 63.52 letters. This remained stable after, at 63.15 letters. The therapeutic strategy used before lockdown was Pro re nata (PRN) in 62.46% and Treat and extend (TAE) in 30.56%. Age related macular degeneration (AMD) was the most common disease (61.13%). In group 2, the average age is 76 y. Female patients represent 58.55%. Average VA before lockdown was 60.77 letters. It was reduced to 50.63 letters after. The predominant therapeutic strategy was PRN (47.05%) followed by TAE (32.62%). AMD was the most common disease (56.68%)

Conclusions : The COVID-19 lockdown severely impacted management of macular diseases by IVIs at CHIC. The short-term impact on VA is significant in the absence of treatment. The impact is not statistically different with respect to age, gender, and retinal disease. However, regarding therapeutic strategy, PRN seems to have enabled a better observance. These results underline the importance of sensitizing patients to treatment observance. They can also contribute to develop effective management strategies for macular diseases during times of crisis

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×